Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review.
- Resource Type
- Case Study
- Authors
- Tomomasa, Dan; Isoda, Takeshi; Mitsuiki, Noriko; Yamashita, Motoi; Morishita, Aoi; Tomoda, Takahiro; Okano, Tsubasa; Endo, Akifumi; Kamiya, Takahiro; Yanagimachi, Masakatsu; Imai, Kohsuke; Kanegane, Hirokazu; Takagi, Masatoshi; Morio, Tomohiro
- Source
- Clinical Case Reports. Dec2021, Vol. 9 Issue 12, p1-9. 9p.
- Subject
- *HEMATOPOIETIC stem cell transplantation
*STEM cell transplantation
*RUXOLITINIB
*LITERATURE reviews
*PNEUMONIA
*IDIOPATHIC interstitial pneumonias
*PNEUMOCYSTIS pneumonia
- Language
- ISSN
- 2050-0904
Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS. [ABSTRACT FROM AUTHOR]